Henry Schein Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Henry Schein stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View analyst ratings for Henry Schein or view top-rated stocks.

Wall Street analysts have given Henry Schein a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Henry Schein wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Henry Schein.

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, February, 16th. The company reported $1.00 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.99 by $0.01. The business had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $2.86 billion. Henry Schein had a net margin of 6.14% and a trailing twelve-month return on equity of 11.60%. During the same period in the prior year, the company earned $0.97 earnings per share.
View Henry Schein's earnings history.

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HSIC shares have increased by 20.3% and is now trading at $69.39.
View which stocks have been most impacted by COVID-19.

Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its board has authorized a stock buyback plan on Thursday, October 31st 2019, which permits the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 4.3% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its shares are undervalued.

Henry Schein updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 17th. The company provided earnings per share (EPS) guidance of 3.51 for the period, compared to the Thomson Reuters consensus estimate of $3.80.

6 equities research analysts have issued 1 year price objectives for Henry Schein's stock. Their forecasts range from $50.00 to $83.00. On average, they anticipate Henry Schein's stock price to reach $68.50 in the next year. This suggests that the stock has a possible downside of 1.3%.
View analysts' price targets for Henry Schein or view top-rated stocks among Wall Street analysts.

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Henry Schein include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Patterson Companies (PDCO) and Owens & Minor (OMI).
View all of HSIC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock is owned by a variety of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.42%), State of Alaska Department of Revenue (0.07%), Pensionfund DSM Netherlands (0.03%), M&R Capital Management Inc. (0.01%), Pacer Advisors Inc. (0.01%) and Everence Capital Management Inc. (0.01%). Company insiders that own Henry Schein stock include Deborah Derby, E Dianne Rekow, Gerald A Benjamin, James P Breslawski, Michael S Ettinger, Paul Brons, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, M&R Capital Management Inc., Pacer Advisors Inc., and Neville Rodie & Shaw Inc.. Company insiders that have sold Henry Schein company stock in the last year include Gerald A Benjamin, and Walter Siegel.
View insider buying and selling activity for Henry Schein or view top insider-selling stocks.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Everence Capital Management Inc., Pensionfund DSM Netherlands, and First Hawaiian Bank.
View insider buying and selling activity for Henry Schein or or view top insider-buying stocks.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSIC stock can currently be purchased for approximately $69.39.

Henry Schein has a market capitalization of $9.87 billion and generates $9.99 billion in revenue each year. The company earns $694.73 million in net income (profit) each year or $3.51 on an earnings per share basis.

Henry Schein employs 19,000 workers across the globe.

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, MEDIVET, Maddox Practice Group, Maravet, Marrodent, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

Henry Schein was founded in 1932.

The official website for Henry Schein is www.henryschein.com.

Henry Schein is headquartered at 135 DURYEA RD, MELVILLE NY, 11747.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500 or via email at [email protected]